business
Karyopharm Therapeutics Q1 Earnings Call Highlights
Key takeaways
- Karyopharm Therapeutics Q1 Earnings Call Highlights Market Beat Fri, May 15, 2026 at 12:09 AM GMT+7 7 min read KPTI Key Points Interested in Karyopharm Therapeutics Inc.?
- First-quarter revenue rose to $35.1 million, and Karyopharm reaffirmed full-year 2026 guidance; however, management said underlying XPOVIO demand was weaker year over year due to increased competition.
- → Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe?
Karyopharm Therapeutics Q1 Earnings Call Highlights Market Beat Fri, May 15, 2026 at 12:09 AM GMT+7 7 min read KPTI Key Points Interested in Karyopharm Therapeutics Inc.? Here are five stocks we like better.
Key clinical catalysts are ahead for Karyopharm, including FDA engagement and publication plans for its Phase 3 SENTRY myelofibrosis trial, plus an expected mid-2026 readout from the endometrial cancer study XPORT-EC-042.
The SENTRY trial showed a statistically significant spleen volume response benefit for selinexor plus ruxolitinib, along with an encouraging overall survival signal and no new safety concerns, though the symptom endpoint was not statistically significant.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Investing.com
Earnings call transcript: Extendicare Inc. Q1 2026 earnings beat estimates
Investing.com
Earnings call transcript: Cellebrite Q1 2026 earnings beat estimates
Investing.com
Earnings call transcript: Grupo Equatorial beats Q1 2026 forecasts
Investing.com
Earnings call transcript: Definity Financial exceeds Q1 2026 expectations
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop